1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1647
  6. Examiner Hama (SPE)

Examiner Hama Joanne (SPE)

1647-HAMA-JOANNE

Employment Information

Art Unit:1647 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
702 — Data processing: measuring, calibrating, or testing
436 — Chemistry: analytical and immunological testing
703 — Data processing: structural design, modeling, simulation, and emulation
Phone:(571) 272-2911
Email:joanne.hama@uspto.gov
Location:VA 22314
Title:Supvy Pat Examnr Biolgy
Service:22 years
Grade:GS-15

Grant Rate and Difficulty Ranking

96
3-Year Grant rate: 10% over 82 cases
Difficulty: Extremely Hard
Difficulty Percentile: 96th

With Examiner Hama (SPE), you have a 10% chance of getting an issued patent by 3 years after the first office action. Examiner Hama (SPE) is an extremely hard examiner and in the 96th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Hama (SPE), where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1647

Examiner Hama (SPE)'s grant rate is lower than that of Art Unit 1647 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Hama (SPE) 1.3
Art Unit 1647 1.5

Interview Benefit

Grant Rate without Interview

Examiner Hama (SPE) has granted 8 of 81 cases without any applicant-requested interviews for a grant rate of 10%.

Grant Rate with Interview

Examiner Hama (SPE) has granted 0 of 1 cases with at least one applicant-requested interview for a grant rate of 0%.

Interview Benefit

With Examiner Hama (SPE), conducting an interview decreases your chance of getting a patent granted by 100%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17631797 Anti-Human P40 Protein Domain Antibody And Use Thereof Rejection information available with a Premium Stats subscription. See our pricing. Patented View
16978285 Inhibitor Of Setdb1 Histone Methyltransferase For Use In Cancer Combination Therapy Abandoned View
17843232 Il-31 Modulators For Treating Fxr-Induced Pruritus Patented View
17808379 Use Of Circulating Interleukin-18 For Prognosticating And Treating Recurrence In Early Stage Non-Small Cell Lung Cancer Patented View
17640412 Bispecific Binding Agent That Binds To Cd117/c-Kit And Cd3 Abandoned View
17441410 Small-Molecule Inhibitor Of Pd-1/pd-L1, Pharmaceutical Composition Thereof With Pd-L1 Antibody, And Application Of Same Abandoned View
17004522 Carbon Monoxide-Releasing Molecule Conjugates And Related Compositions And Methods Abandoned View
17674371 Treatment Of Sarcoma Using Immunomodulation Abandoned View
17322827 Sting Agonist Combination Treatments With Immune Checkpoint Inhibitors Abandoned View
15734974 Cd33 Monocytes As A Biomarker Abandoned View
16973627 Chimeric Antigen Receptor Tumor Infiltrating Lymphocytes Abandoned View
18210873 Theophylline-Loaded Collagen Nanoparticles Abandoned View
16921626 Compositions And Methods For Enhancing Cell Culture Abandoned View
15733313 Antibodies And Variants Thereof Against Pd-L1 Patented View
17138485 Combination Therapy Comprising A2a/a2b And Pd-1/pd-L1 Inhibitors Abandoned View
17265704 Antibodies Against Dengue Virus And Related Methods Patented View
17328816 Prediction Of Clinical Response To Il23-Antagonists Using Il23 Pathway Biomarkers Abandoned View
17043952 Methods For Predicting And Enhancing Therapeutic Benefit From Checkpoint Inhibitors In Cancer Abandoned View
17267410 New Car Constructs Comprising Tnfr2 Domains Abandoned View
16937483 Triptolide Antibody Conjugates Abandoned View
17271149 Combination Therapies Comprising Cd137/her2 Bispecific Agents And Pd-1 Axis Inhibitors And Uses Thereof Abandoned View
17274082 Anti-Cd38 Antibody, Antigen-Binding Fragment Thereof, And Pharmaceutical Use Abandoned View
16469494 Immunoconjugates Targeting Adam9 And Methods Of Use Thereof Abandoned View
17252160 Oxabicycloheptanes For Enhancing Car T Cell Function Abandoned View
17467714 Methods Of Using Surufatinib In Treating Advanced Pancreatic And Extra-Pancreatic Neuroendocrine Tumors Abandoned View
17266450 Use Of Tim-3 Antibody In Preparation Of Medicines For Treating Tumors Abandoned View
17933133 Combination Therapy Using Antibody To Human Siglec-9 And Antibody To Human Nkg2a For Treating Cancer Abandoned View
17525731 Triple Combination To Treat B-Cell Malignancies Abandoned View
16980631 Combination Therapy For Ttr Amyloidosis Abandoned View
16981806 Novel Anti-Ctla-4 Antibody Polypeptide Abandoned View
17154137 Human Antibody Specific For Interleukin-1alpha Abandoned View
17044163 Methods Of Treating Tumor Abandoned View
16878534 Method Of Treating A Metabolic Disorder Of The Liver Abandoned View
16764246 Combinations Of Irs/stat3 Dual Modulators And Anti Pd-1/pd-L1 Antibodies For Treating Cancer Abandoned View
16966100 Methods For Treating Cancer Or Infection Using A Combination Of An Anti-Pd-1 Antibody, An Anti-Lag3 Antibody, And An Anti-Tigit Antibody Abandoned View
16962805 Methods Of Treating Cancer With Antibodies Against Tim3 Abandoned View
16925068 Molecules, Compositions And Methods For Treatment Of Cancer Abandoned View
16479095 Combination Therapy For The Treatment Of Cancer Abandoned View
17033469 Anti-Il-27 Antibodies And Uses Thereof Abandoned View
17154959 Bivalent Chimeric Engulfment Receptors And Uses Thereof Abandoned View
17387218 Neutralizing Mono-Specific Igy Antibodies To Inhibit Or Treat Sars-Cov-2 Coronavirus Infection Abandoned View
16956765 Use Of Combined Treatment Of Pd-1 Antibody And Apatinib For Treating Triple Negative Breast Cancer Abandoned View
16718866 Antibodies To Pmel17 And Conjugates Thereof Patented View
16649133 Tumor Suppression Using Human Placenta-Derived Intermediate Natural Killer (Pink) Cells In Combination With An Antibody Abandoned View
17048119 Muc16 Monoclonal Antibody And Uses Thereof Patented View
16323442 Anti-Siglec-7 Antibodies For The Treatment Of Cancer Patented View
16635383 Methods And Compositions For The Treatment Of Cancer Abandoned View
16966409 Antibody Drug Conjugates (Adcs) With Nampt Inhibitors Abandoned View
16624648 Interferon Prodrug For The Treatment Of Cancer Abandoned View
16626170 Methods For Preventing And Treating Urinary Incontinence Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.